Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Heritage Bio Labs

Research Library

Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.

Browse by productGeneral topics

Find articles

Matching articles

Showing 49–60 of 134 articles · Explore study findings

Clear search and filters

  • Explore study findings

    What patients and blinded evaluators saw after laser resurfacing

    GHK-Cu is the copper complex of a three-amino-acid peptide. An older randomized study published in 2006 examined whether products containing this complex changed recovery or appearance after carbon dioxide laser resurfacing. Thirteen participants completed the study.

    GHK-Cu1 source (2006)

  • Explore study findings

    What Japan's diagnostic approval covers

    GHRP-2 is a synthetic six-residue peptide, also called pralmorelin, that stimulates growth hormone (GH) release through the growth hormone secretagogue system. Japan approved a pralmorelin hydrochloride product as a diagnostic agent for evaluating impaired GH secretion.

    GHRP-22 sources (2007, 2025)

  • Explore study findings

    Why preventing a raised scar differs from reversing one

    GHRP-6 is a synthetic six-residue peptide that activates the ghrelin receptor and promotes growth hormone release in experimental settings. An animal study asked whether exposure to GHRP-6 changed the development of a raised scar or the appearance of an already mature scar.

    GHRP-62 sources (2018, 2021)

  • Explore study findings

    Why a human blood study reported two half-lives

    GHRP-6 is a six-residue synthetic growth hormone–releasing peptide. In a small human study, researchers asked which mathematical model best described the decline of GHRP-6 itself in blood. No recent primary human study directly repeating this time-course experiment was identified.

    GHRP-61 source (2012)

  • Explore study findings

    Why Copper’s Chemical Form Matters When Reading GLOW Research

    Peptides are short chains made by linking amino acids through peptide bonds. A chain can sometimes bind a metal ion. That is the case for GHK-Cu, the copper complex of a three-amino-acid peptide and one ingredient named in descriptions of GLOW.

    GLOW Blend1 source (2026)

  • Explore study findings

    What a Copper Peptide Hydrogel Study Adds to the GLOW Discussion

    GLOW is a label for a mixture of research materials that can include GHK-Cu, a peptide bound to copper. A 2026 paper used GHK-Cu in an engineered hydrogel for an infected diabetic wound model.

    GLOW Blend1 source (2026)

  • Explore study findings

    What a Mouse Mitochondria Study Can Explain About One GLOW 2 Ingredient

    GLOW 2, as described in the catalog, includes a material named MOTS-c alongside GHK-Cu and BPC-157. The exact blend formulation remains unconfirmed.

    GLOW 2 Blend1 source (2026)

  • Explore study findings

    What the 2026 MOTS c Appraisal Means for Claims About GLOW 2

    The GLOW 2 formulation described in the catalog names the mitochondrial peptide MOTS-c together with GHK-Cu and BPC-157. The exact preparation has not been confirmed. Federal documents that discuss MOTS-c provide useful context for assessing what is known about that ingredient.

    GLOW 2 Blend2 sources (2026)

  • Explore study findings

    What three semaglutide trials tell us about kidney outcomes

    Semaglutide is a modified peptide that activates the glucagon-like peptide-1, or GLP-1, receptor. It is used in several approved formulations for specific conditions.

    GLP-1 SEMA2 sources (2026)

  • Explore study findings

    What BARI-STEP found after bariatric surgery

    Semaglutide is a modified GLP-1 receptor agonist peptide. In the 2026 BARI-STEP trial, researchers tested whether it affected body weight in adults who had lost less weight than the study’s threshold after bariatric surgery.

    GLP-1 SEMA2 sources (2026)

  • Explore study findings

    What two Alzheimer’s trials found about oral semaglutide

    Semaglutide is a modified GLP-1 receptor agonist. Researchers investigated whether its oral form could slow progression in people with early symptomatic Alzheimer’s disease. Two phase 3 trials reported in 2026 compared it with placebo.

    GLP-1 SEMA2 sources (2026)

  • Explore study findings

    What a 2026 analysis found across sleep apnea subgroups

    Tirzepatide is a modified peptide that activates the GIP and GLP-1 receptors. “GLP-2 TIRZ” is the catalog label. Tirzepatide’s tested targets are GIP and GLP-1, distinct from the GLP-2 receptor. A 2026 analysis asked how sleep apnea outcomes varied with participants’ starting characteristics.

    GLP-2 TIRZ3 sources (2022–2026)

Browse by product

General topics

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Library index (JSON)